{"entity":{"id":"sabine-linn","kind":"person","name":"Sabine Linn","aka":[],"tldr":"Sabine Linn is a breast oncologist testing DNA-damaging chemotherapy in BRCA-like breast cancer.","summary":"Sabine Linn is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL) and Professor at Utrecht. Her specialisms are breast cancer, BRCA-like tumours and neoadjuvant trials, with a focus on BRCA1/BRCA2 and homologous recombination deficiency in triple-negative disease. She leads breast cancer trials at NKI, including studies of high-dose alkylating chemotherapy in BRCA1-like tumours and of neoadjuvant immunotherapy. Her papers include the TRAIN-2 phase 3 trial of neoadjuvant chemotherapy with or without anthracyclines alongside dual HER2 blockade and its three-year follow-up, and a study of stromal tumour-infiltrating lymphocytes in young, node-negative, triple-negative patients who received no systemic therapy. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Linn%20SC%5BAuthor%5D%20BRCA-like%20breast"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":["brca"],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":["hrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist and Group Leader, Netherlands Cancer Institute; Professor, Utrecht","institutionId":"nki","specialisms":["Breast cancer","BRCA-like tumours","Neoadjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Linn%20SC%5BAuthor%5D%20BRCA-like%20breast"}],"papers":[{"title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(18)30570-9"},{"title":"Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy","journal":"Journal of Clinical Oncology","year":2022,"doi":"10.1200/jco.21.01536"},{"title":"Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2 -Positive Breast Cancer","journal":"JAMA Oncology","year":2021,"doi":"10.1001/jamaoncol.2021.1371"}],"orcid":"0000-0001-5541-0347"},"route":"/people/sabine-linn/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"}],"institution":[{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/"}],"term":[{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/"}]}}